2022
A stated preference survey to explore patient preferences for novel preventive migraine treatments
Hubig L, Smith T, Chua G, Lloyd A, Powell L, Johnston K, Harris L, L'Italien G, Coric V, Lo S. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache The Journal Of Head And Face Pain 2022, 62: 1187-1197. PMID: 36047857, PMCID: PMC9826196, DOI: 10.1111/head.14386.Peer-Reviewed Original ResearchConceptsPatient preferencesTreatment effectivenessCGRP inhibitorsMigraine frequencyMigraine severityPreventive treatmentOral tabletsSemi-structured patient interviewsOnline discrete choice experiment surveyCalcitonin gene-related peptide (CGRP) inhibitorsPreventive migraine treatmentMonoclonal antibody treatmentSeverity of migraineMode of administrationDiscrete choice experiment surveyHypothetical treatment choicesQuarterly injectionsMonthly injectionsOral therapyAntibody treatmentMigraine treatmentPrescribing choicesPatient interviewsSubgroup analysisTreatment preferencesReal-World experience of interictal burden and treatment in migraine: a qualitative interview study
Lo S, Gallop K, Smith T, Powell L, Johnston K, Hubig L, Williams E, Coric V, Harris L, L’Italien G, Lloyd A. Real-World experience of interictal burden and treatment in migraine: a qualitative interview study. The Journal Of Headache And Pain 2022, 23: 65. PMID: 35676636, PMCID: PMC9174626, DOI: 10.1186/s10194-022-01429-5.Peer-Reviewed Original ResearchConceptsMigraine attacksInterictal burdenMigraine symptomsPreventive treatmentHealth-related qualityMonoclonal antibody treatmentSubgroup of patientsEffective treatment optionSelf-reported diagnosisBreakthrough attacksCGRP mAbsHRQL impactAntibody treatmentMigraine painMigraine treatmentTreatment optionsTreatment administrationQualitative interview studyMigraine impactLifestyle changesPatient's perspectiveTreatment experienceSide effectsPatient experienceConclusionThis study
2019
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal Of Medicine 2019, 381: 142-149. PMID: 31291516, DOI: 10.1056/nejmoa1811090.Peer-Reviewed Original ResearchConceptsPercentage of patientsPeptide receptor antagonistPlacebo groupMigraine attacksBothersome symptomsReceptor antagonistCalcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptorGene-related peptide receptorOral Calcitonin GeneSingle migraine attackAcute migraine treatmentCommon adverse eventsPrimary end pointPhase 3 trialUrinary tract infectionOverall mean agePathogenesis of migraineModified intentionAdverse eventsTract infectionsTreat analysisMean ageMigraine treatmentCalcitonin gene